Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro

European Journal of Pharmacology

Volumn 572, Issue 2-3, 2007, Pages 102-110

  Kellinsalmi, Maarit ^a   Parikka, Vilhelmiina ^b   Risteli, Juha ^a   Hentunen, Teuvo ^b   Leskelä, Hannu Ville ^a   Lehtonen, Siri ^a   Selander, Katri ^c   Väänänen, Kalervo ^b   Lehenkari, Petri ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c University of Alabama at Birmingham   (United States)

Author keywords

Adipocyte; Cyclooxygenase; Human mesenchymal stem cell; Parecoxib

Indexed keywords

CYCLOOXYGENASE 2; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PARECOXIB;

ADIPOCYTE; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FRACTURE HEALING; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; RAT;

ADIPOCYTES; ANIMALS; CATTLE; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INDOMETHACIN; ISOXAZOLES; MALE; MESENCHYMAL STEM CELLS; MICE; NITROBENZENES; OSTEOBLASTS; OSTEOCLASTS; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 34548794103     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.030     Document Type: Article

References (39)

1. Alatalo S.L., Halleen J.M., Hentunen T.A., Mönkkönen J., and Väänänen H.K. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin. Chem. 46 (2000) 1751-1754
2. Barnes G.L., Kostenuik P.J., Gerstenfeld L.C., and Einhorn T.A. Growth factor regulation of fracture repair. J. Bone Miner. Res. 14 (1999) 1805-1815
3. Birk R.Z., Abramovitch-Gottlib L., Margalit I., Aviv M., Forti E., Geresh S., and Vago R. Conversion of adipogenic to osteogenic phenotype using crystalline porous biomatrices of marine origin. Tissue Eng. 12 (2006) 21-31
4. Botting R., and Ayoub S.S. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot. Essent. Fat. Acids 72 (2005) 85-87
5. Boyde A., Ali N.N., and Jones S.J. Resorption of dentine by isolated osteoclasts in vitro. Br. Dent. J. 156 (1984) 216-220
6. Brown K.M., Saunders M.M., Kirsch T., Donahue H.J., and Reid J.S. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J. Bone Joint Surg. Am. 86A (2004) 116-123
7. Chambers T.J., Thomson B.M., and Fuller K. Effect of substrate composition on bone resorption by rabbit osteoclasts. J. Cell. Sci. 70 (1984) 61-71
8. Choi B.K., Moon S.Y., Cha J.H., Kim K.W., and Yoo Y.J. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola and Treponema socranskii. J. Periodontol. 76 (2005) 813-820
9. Deshimaru R., Ishitani K., Makita K., Horiguchi F., and Nozawa S. Analysis of fatty acid composition in human bone marrow aspirates. Keio J. Med. 54 (2005) 150-155
10. Einhorn T.A. The cell and molecular biology of fracture healing. Clin. Orthop. 355 (1998) 7-21
11. Gerstenfeldt L.C., Thiede M., Seibert K., Mielke C., Phippard D., Svagr B., Cullinane D., and Einhorn T.A. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J. Orthop. Res. 21 (2003) 670-675
12. Gierse J.K., Koboldt C.M., Walker M.C., Seibert K., and Isakson P.C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 339 (1999) 607-614
13. Giordano V., Giordano M., Knackfuss I.G., Apfel M.I.R., and Gomes R.D.C. Effect of tenoxicam on fracture healing in rat tibia. Injury 34 (2003) 85-94
14. Glassman S.D., Rose S.M., Dimar J.R., Puno R.M., Campbell M.J., and Johnson J.R. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1 (1998) 834-838
15. Goodman S., Ma T., Trindade M., Ikenoue T., Matsuura I., Wong N., Fox N., Genovese M., Regula D., and Smith R.L. COX-2 selective NSAID decreases bone ingrowth in vivo. J. Orthop. Res. 20 (2002) 1164-1169
16. Gregoire F.M., Smas C.M., and Sul H.S. Understanding adipocyte differentiation. Physiol. Rev. 78 (1998) 697-710
17. Ha H., Lee J.H., Kim H.M., Kwak H.B., Lee S., Kim H.H., and Lee Z.H. Alpha-lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J. Immunol. 1 (2006) 111-117
18. Im G.I., Kwon B.C., and Lee K.B. The effect of COX-2 inhibitors on periprosthetic osteolysis. Biomaterials 25 (2004) 269-275
19. Kis B., Snipes J.A., and Busija D.W. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions and uncertainties. J. Pharmacol. Exp. Ther. 315 (2005) 1-7
20. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M.T., Martin T.J., and Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103 9 (1999) 1345-1352
21. Leskelä H.V., Risteli J., Niskanen S., Koivunen J., Ivaska K.K., and Lehenkari P. Osteoblast recruitment from stem cells does not decrease by late adulthood. Biochem. Biophys. Res. Commun. 311 (2003) 1008-1013
22. Li X., Cui Q., Kao C., Wang G.J., and Balian G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33 (2003) 652-659
23. Li L., Pettit A.R., Gregory L.S., and Forwood M.R. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name 1/4. Cytokine Growth Factor Rev. 17 (2006) 203-216
24. Liu X.H., Kirschenbaum A., Yao S., and Levine A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signalin systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-(kappa)B (RANK) ligand/RANK system. Endocrinology 146 (2005) 1991-1998
25. Long J., Lewis S., Kuklo T., Zhu Y., and Riew K.D. The effect of cyclooxygenase-2 inhibitors on spinal fusion. J. Bone Joint Surg. Am. 84A (2002) 1763-1768
26. Noor M., and Gajraj F.R.C.A. The effect of cyclooxygenase-2 inhibitors on bone healing. Reg. Anesth. Pain Med. 28 (2003) 456-465
27. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., and Pilbeam C.C. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105 6 (2000) 823-832
28. Okada Y., Pilbeam C., Raisz L., and Tanaka Y. Role of cyclooxygenase-2 in bone resorption. J. UOEH 1 (2003) 185-195
29. Ozaki A., Tsunoda M., Kinoshita S., and Saura R. Role of fracture haematoma and periosteum during fracture healing in rats: interaction of fracture haematoma and the periosteum in the initial step of the healing process. J. Orthop. Sci. (2000) 64-70
30. Rawlinson S.C., Wheeler-Jones C.P., and Lanyon L.E. Arachinodic acid for loading induced prostacyclin and prostaglandin E(2) release from osteoblasts and osteocytes is derived from the activities of different forms of phospholipase A(2). Bone 27 (2000) 241-247
31. Reuben S.S., and Ekman E.F. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J. Bone Joint Surgery Am. 87 (2005) 536-542
32. Sato T., Morita I., and Murota S. Prostaglandin E2 mediates parathyroid hormone induced osteoclast formation by cyclic AMP independent mechanism. Adv. Exp. Med. Biol. 407 (1997) 383-386
33. Selander K., Lehenkari P., and Väänänen H.K. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif. Tissue Int. 55 (1994) 368-375
34. Selander K.S., Mönkkönen J., Karhukorpi E.K., Härkönen P., Hannuniemi R., and Väänänen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50 (1996) 1127-1138
35. Simon A.M., Manigrasso M.B., and O'Connor J.P. Cyclo-oxygenase 2 function is essential for bone fracture healing. J. Bone Miner. Res. 17 (2002) 963-976
36. Wei X., Zhang X., Zuscik M.J., Drissi M.H., Schwarz E.M., and O'Keefe R.J. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J. Bone Miner. Res. 20 (2005) 1136-1148
37. Yan H., Kermouni A., Abdel-Hafez M., and Lau D.C.W. Role of cyclooxygenase COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells. J. Lipid. Res. 44 (2003) 424-429
38. Yokota T., Meka C.S.R., Medina K.L., Igarashi H., Comp P.C., Takahashi M., Nishida M., Oritani K., Miyagawa J.-I., Funahashi T., Tomiyama Y., Matsuzawa Y., and Kincade P.W. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J. Clin. Invest. 109 (2002) 1303-1310
39. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., and O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation in to the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 1 (2002) 1405-1415